CYTK Cytokinetics Incorporated

+0.07  (+1%)
Previous Close 8.75
Open 8.7
Price To Book 18.75
Market Cap 483840973
Shares 54,888,369
Volume 225,304
Short Ratio
Av. Daily Volume 551,420

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data to be presented May 5, 2019, 1:11 PM.
Reldesemtiv (CK-2127107) - FORTITUDE-ALS
Amyotrophic lateral sclerosis (ALS)
Phase 1b interim analysis noted lack of efficacy.
Limited mobility
Phase 2 data presented June 16, 2018.
Spinal muscular atrophy (SMA)
Phase 3 interim analysis March 20, 2019 noted trial to continue as planned. Enrolment to be completed 1H 2019.
Omecamtiv mecarbil GALACTIC-HF
Acute heart failure
Phase 3 data released November 21, 2017 - primary endpoint not met.
Tirasemtiv - VITALITY
Amyotrophic lateral sclerosis (ALS)
Phase 2 data did not meet endpoints - October 5, 2018.
Reldesemtiv (CK-2127107)
Chronic obstructive pulmonary disease (COPD)
Second Phase 3 trial initiation announced February 21, 2019.
Omecamtiv mecarbil METEORIC-HF
Acute heart failure
Phase 1 initiation announced December 5, 2018. Data due 2019.
Healthy volunteers (hypertrophic cardiomyopathy (HCM))
Phase 1 trial initiation announced February 20, 2019.
AMG 594
Healthy volunteers

Latest News

  1. The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering
  2. Here's Why Cytokinetics Stock Jumped Today
  3. Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
  4. Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
  5. Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at ACC.19
  6. Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at ACC.19
  7. Edited Transcript of CYTK earnings conference call or presentation 21-Feb-19 9:30pm GMT
  8. Cytokinetics Announces Presentation of Results From FORTITUDE-ALS at the American Academy of Neurology 71st Annual Meeting
  9. Some Cytokinetics Shareholders Are Down 43%
  10. Cytokinetics Inc (CYTK) Files 10-K for the Fiscal Year Ended on December 31, 2018
  11. Cytokinetics Joins Global Initiative To Recognize International Rare Disease Day
  12. Amgen Starts Phase III Enrollment for Heart Failure Drug
  13. Cytokinetics Inc (CYTK) Q4 2018 Earnings Conference Call Transcript
  14. Cytokinetics (CYTK) Reports Q4 Loss, Tops Revenue Estimates
  15. Cytokinetics: 4Q Earnings Snapshot
  16. Cytokinetics Reports Fourth Quarter 2018 Financial Results
  17. Amgen, Cytokinetics and Servier Announce Start of METEORIC-HF, the Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
  18. Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
  19. Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator
  20. The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna